Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist

2015 ◽  
Vol 138 (8) ◽  
pp. 2021-2029 ◽  
Author(s):  
Míriam Toledo ◽  
Sílvia Busquets ◽  
Fabio Penna ◽  
Xiaolan Zhou ◽  
Enrica Marmonti ◽  
...  
Keyword(s):  
Cancer Cachexia ◽  
Muscle Wasting ◽  
Type Ii ◽  
Additive Effects ◽  
Experimental Cancer ◽  
Receptor Inhibition ◽  
Complete Reversal

scholarly journals Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia

2017 ◽  
Vol 8 ◽  
Author(s):  
Fabrizio Pin ◽  
Valerio G. Minero ◽  
Fabio Penna ◽  
Maurizio Muscaritoli ◽  
Roberta De Tullio ◽  
...  
Keyword(s):  
Cancer Cachexia ◽  
Muscle Wasting ◽  
Experimental Cancer

scholarly journals The AP-1/NF-κB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia

2007 ◽  
Author(s):  
Rodrigo Moore-Carrasco ◽  
Sílvia Busquets ◽  
Vanessa Almendro ◽  
Moorthy Palanki ◽  
Francisco López-Soriano ◽  
...  
Keyword(s):  
Cancer Cachexia ◽  
Muscle Wasting ◽  
Experimental Cancer

scholarly journals Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of β2-Adrenergic Agonists

2007 ◽  
Vol 67 (13) ◽  
pp. 6512-6519 ◽  
Author(s):  
Gemma Fuster ◽  
Sílvia Busquets ◽  
Elisabet Ametller ◽  
Mireia Olivan ◽  
Vanessa Almendro ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Cancer Cachexia ◽  
Muscle Wasting ◽  
Peroxisome Proliferator ◽  
Adrenergic Agonists ◽  
Skeletal Muscle Wasting ◽  
Experimental Cancer ◽  
Peroxisome Proliferator Activated Receptors

Inhibition of HSP90 reverses STAT3‐mediated muscle wasting in cancer cachexia mice

2021 ◽  
Author(s):  
Mengyuan Niu ◽  
Shiyu Song ◽  
Zhonglan Su ◽  
Lulu Wei ◽  
Li Li ◽  
...  
Keyword(s):  
Cancer Cachexia ◽  
Muscle Wasting

Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging

2021 ◽  
Author(s):  
Alexandra Moreira-Pais ◽  
Rita Ferreira ◽  
Paula A. Oliveira ◽  
José A. Duarte
Keyword(s):  
Cancer Cachexia ◽  
Muscle Wasting

Altered expression of skeletal muscle myosin isoforms in cancer cachexia

2002 ◽  
Vol 283 (5) ◽  
pp. C1376-C1382 ◽  
Author(s):  
Gary M. Diffee ◽  
Katherine Kalfas ◽  
Sadeeka Al-Majid ◽  
Donna O. McCarthy
Keyword(s):  
Muscle Atrophy ◽  
Cancer Cachexia ◽  
Muscle Wasting ◽  
Tumor Cell Line ◽  
Protein Isoforms ◽  
Type I ◽  
Myosin Isoforms ◽  
Skeletal Muscle Myosin ◽  
Altered Expression ◽  
Isoform Expression

Cachexia is commonly seen in cancer and is characterized by severe muscle wasting, but little is known about the effect of cancer cachexia on expression of contractile protein isoforms such as myosin. Other causes of muscle atrophy shift expression of myosin isoforms toward increased fast (type II) isoform expression. We injected mice with murine C-26 adenocarcinoma cells, a tumor cell line that has been shown to cause muscle wasting. Mice were killed 21 days after tumor injection, and hindlimb muscles were removed. Myosin heavy chain (MHC) and myosin light chain (MLC) content was determined in muscle homogenates by SDS-PAGE. Body weight was significantly lower in tumor-bearing (T) mice. There was a significant decrease in muscle mass in all three muscles tested compared with control, with the largest decrease occurring in the soleus. Although no type IIb MHC was detected in the soleus samples from control mice, type IIb comprised 19% of the total MHC in T soleus. Type I MHC was significantly decreased in T vs. control soleus muscle. MHC isoform content was not significantly different from control in plantaris and gastrocnemius muscles. These data are the first to show a change in myosin isoform expression accompanying muscle atrophy during cancer cachexia.

scholarly journals Mathematical Model of Muscle Wasting in Cancer Cachexia

2020 ◽  
Author(s):  
Suzan Farhang-Sardroodi ◽  
Kathleen P. Wilkie
Keyword(s):  
Mathematical Model ◽  
Satellite Cell ◽  
Muscle Tissue ◽  
Cancer Cachexia ◽  
Muscle Wasting ◽  
Tissue Growth ◽  
Colon 26 ◽  
Treatment Conditions ◽  
Risk Of Mortality ◽  
Pharmacological Blockade

Cancer cachexia is a debilitating condition characterized by an extreme loss of skeletal muscle mass which negatively impacts patient’s quality of life, reduces their ability to sustain anticancer therapies, and increases the risk of mortality. Recent discoveries have identified the myostatin/activin-ActRIIB pathway as critical to muscle wasting by inducing satellite cell quiescence and increasing muscle-specific ubiquitin ligases responsible for atrophy. Remarkably, pharmacological blockade of the ActRIIB pathway has shown to reverse muscle wasting and prolong the survival time of tumor-bearing animals. To explore the implications of this signaling pathway and potential therapeutic targets in cachexia, we construct a novel mathematical model of muscle tissue subjected to tumor-derived cachexic factors. The model formulation tracks the intercellular interactions between cancer, satellite cell, and muscle cell populations. The model is parameterized by fitting to colon-26 mouse model data, and analysis provides insight into tissue growth in healthy, cancerous, and post-treatment conditions. Model predictions suggest that cachexia fundamentally alters muscle tissue health, as measured by the stem cell ratio, and this is only partially recovered by anti-cachexia treatment. Our mathematical findings suggest that the activation and proliferation of satellite cells, after blocking the myostatin/activin B pathway, is required to partially recover cancer-induced muscle loss.

Sign in / Sign up

Export Citation Format

Share Document